Dr. Patil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Cleveland, OH 44195Phone+1 502-526-6835Fax+1 215-456-7926
Education & Training
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2010 - 2013
Seth G.S. Medical CollegeClass of 2008
Certifications & Licensure
NY State Medical License 2023 - 2025
OH State Medical License 2013 - 2024
PA State Medical License 2010 - 2013- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 229 citationsManagement of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.John A Thompson, Bryan J Schneider, Julie Brahmer, Amaka Achufusi, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2022-04-01 - 5 citationsThe promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer.Pradnya D. Patil, Brian P. Hobbs, Nathan A. Pennell
Journal of Thoracic Disease. 2019-02-01 - 1 citationsAn Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung CancerPradnya D. Patil, Marc A. Shapiro, Nooshin Hashemi Sadraei, Nathan A. Pennell
The Oncologist. 2019-04-01
Lectures
- Impact of invasive regional lymph node examination (IRLNE) and time to radiation on overall survival for patients with stage I NSCLC treated with SBRT- a NCDB analysis.2019 ASCO Annual Meeting - 6/1/2019
- Incidence and patterns of immune related adverse events (irAEs) during chemoimmunotherapy (ChemoIO) in patients with advanced nonsquamous NSCLC.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Neutrophil to Lymphocyte Ratio Influences Impact of Steroids on Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Brain MetastasesApril 5th, 2021
Artificial Intelligence Identifies Lung Cancer Patients at Risk of Harm Caused by ImmunotherapyFebruary 9th, 2021- AI Technology Can Help Prevent Adverse Effect of Immunotherapy in Certain Lung Cancer PatientsFebruary 5th, 2021
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
